Harmony Biosciences Holdings, which markets a therapy for adult narcolepsy in the US, raised $128 million by offering 5.3 million shares above the proposed range at $24. The company originally planned to offer 4.7 million shares at a range of $20 to $23. At IPO, Harmony Biosciences raised 28% more in proceeds than anticipated.
Harmony Biosciences plans to list on the Nasdaq under the symbol HRMY. Goldman Sachs, Jefferies and Piper Sandler acted as lead managers on the deal.
